WO2005076000A1 - Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr - Google Patents
Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr Download PDFInfo
- Publication number
- WO2005076000A1 WO2005076000A1 PCT/ES2005/000046 ES2005000046W WO2005076000A1 WO 2005076000 A1 WO2005076000 A1 WO 2005076000A1 ES 2005000046 W ES2005000046 W ES 2005000046W WO 2005076000 A1 WO2005076000 A1 WO 2005076000A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epcr
- amino acid
- acid sequence
- polypeptide
- autoantibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 230000007170 pathology Effects 0.000 title claims description 20
- 238000011161 development Methods 0.000 title description 4
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 claims abstract description 63
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 claims abstract description 58
- 108091007231 endothelial receptors Proteins 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 238000011002 quantification Methods 0.000 claims abstract description 12
- 150000001413 amino acids Chemical group 0.000 claims description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 206010055690 Foetal death Diseases 0.000 claims description 39
- 208000001951 Fetal Death Diseases 0.000 claims description 38
- 231100000479 fetal death Toxicity 0.000 claims description 38
- 208000019553 vascular disease Diseases 0.000 claims description 37
- 108020001507 fusion proteins Proteins 0.000 claims description 32
- 102000037865 fusion proteins Human genes 0.000 claims description 32
- 208000007536 Thrombosis Diseases 0.000 claims description 29
- 208000023275 Autoimmune disease Diseases 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 17
- 238000000746 purification Methods 0.000 claims description 17
- 101001012038 Homo sapiens Endothelial protein C receptor Proteins 0.000 claims description 14
- 102000051068 human PROCR Human genes 0.000 claims description 14
- 206010047249 Venous thrombosis Diseases 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 11
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 11
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 11
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 11
- 238000004873 anchoring Methods 0.000 claims description 11
- 235000014304 histidine Nutrition 0.000 claims description 11
- 230000004089 microcirculation Effects 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 6
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 6
- 208000002296 eclampsia Diseases 0.000 claims description 6
- 208000030941 fetal growth restriction Diseases 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010036590 Premature baby Diseases 0.000 claims description 5
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 5
- 206010000210 abortion Diseases 0.000 claims description 5
- 231100000176 abortion Toxicity 0.000 claims description 5
- 201000004988 autoimmune vasculitis Diseases 0.000 claims description 5
- 201000011461 pre-eclampsia Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 206010002329 Aneurysm Diseases 0.000 claims description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
- 208000005107 Premature Birth Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 201000002818 limb ischemia Diseases 0.000 claims description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
- 230000001052 transient effect Effects 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 150000002411 histidines Chemical class 0.000 claims description 3
- 238000010324 immunological assay Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 2
- 102000000584 Calmodulin Human genes 0.000 claims description 2
- 108010041952 Calmodulin Proteins 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 2
- 241001195348 Nusa Species 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 108010018381 streptavidin-binding peptide Proteins 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 abstract description 36
- 101800001700 Saposin-D Proteins 0.000 abstract description 36
- 229960000856 protein c Drugs 0.000 abstract description 36
- 238000001514 detection method Methods 0.000 abstract description 7
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 2
- 102000017975 Protein C Human genes 0.000 description 34
- 239000003146 anticoagulant agent Substances 0.000 description 26
- 229940127219 anticoagulant drug Drugs 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 238000001994 activation Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 206010003178 Arterial thrombosis Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000003429 anti-cardiolipin effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 206010025135 lupus erythematosus Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102100030024 Endothelial protein C receptor Human genes 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 108010079274 Thrombomodulin Proteins 0.000 description 4
- 102000012607 Thrombomodulin Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 108010042591 activated protein C receptor Proteins 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- -1 anionic phospholipids Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000036213 phospholipid binding proteins Human genes 0.000 description 2
- 108091011000 phospholipid binding proteins Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- WPVINHLVHHPBMK-ULQDDVLXSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCN1C(=O)[C@@H]1CCC(=O)N1 WPVINHLVHHPBMK-ULQDDVLXSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010021561 4-Nitrophenylphosphatase Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101001120470 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Peptidoglycan-associated lipoprotein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 1
- 108010070519 PAR-1 Receptor Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009593 intrauterine fetal growth Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000033962 signal peptide processing Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Definitions
- the present invention relates to a method for detecting high levels of autoantibodies against the endothelial receptor of activated protein C / protein C (EPCR) in a sample, by in vitro detection and quantification.
- EPCR activated protein C / protein C
- Autoimmune diseases are diseases that are characterized by the presence of immunological reactions in which something triggers the reaction of the immune system against the body's own tissues and the production of abnormal antibodies that attack said tissues (autoantibodies ).
- autoimmune diseases include antiphospholipid syndrome (FAS), rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis in general, etc.
- FAS is characterized by vascular thrombosis (venous, arterial or microvascular) and complications in pregnancy (fetal death, premature birth or multiple spontaneous abortion) associated with the presence of antiphospholipid antibodies.
- antiphospholipid antibodies are heterogeneous and recognize a variety of combinations of phospholipids, phospholipid binding proteins or both.
- the most commonly detected subgroups of antiphospholipid antibodies are lupus anticoagulant antibodies (ACL), anticardiolipin antibodies and antibodies antiglycoprotein I ⁇ 2.
- ACL lupus anticoagulant antibodies
- Other antiphospholipid antibodies not included in the classic laboratory criteria are currently under study.
- Such antibodies are directed against phospholipids other than cardiolipin, such as phosphatidylethanolamine, or against phospholipid binding proteins, such as annexin V and protein S.
- phospholipid binding proteins such as annexin V and protein S.
- Vascular diseases are of three fundamental types depending on the type of vessel affected (arterial, venous or small-sized vessels of the microcirculation).
- a sclerosis of its wall occurs that decreases the flow through its light and, therefore, chronically decreases the influx of blood to the territories irrigated by that injured artery.
- Atherosclerotic lesion can complicate and cause a thrombus inside the artery by completely plugging the vessel and thus closing the blood flow, in which case a heart attack occurs.
- the most frequent are myocardial infarction when the thrombosed artery is a coronary artery and cerebral infarction when the thrombosed artery is an artery that waters the brain.
- thrombosis causes a difficulty in the return of blood to the heart.
- a fragment of the thrombus of the thrombosed venous wall is released then it will migrate until it remains trapped in the pulmonary venous circulation, causing acute pulmonary insufficiency, known as pulmonary embolism.
- the diseases of the microcirculation are caused by inflammation and / or thrombosis of the vessels of the microcirculation of the different organs and are manifested as a failure of the function of the organ whose microcirculation is damaged.
- Vascular diseases constitute an important cause of morbidity and mortality in western countries.
- cardiovascular diseases are the leading cause of death in Spain (approximately 35.0% of total deaths).
- vascular or thrombotic arterial diseases of the heart mainly acute myocardial infarction
- thrombotic arterial diseases of the heart mainly acute myocardial infarction
- antiphospholipid antibodies Several molecular risk factors are currently known that may explain the occurrence of thrombosis in some patients, one of these risk factors is the presence of so-called antiphospholipid antibodies.
- antiphospholipid antibodies Originally it was thought that these autoantibodies were directed against anionic phospholipids; however, it has subsequently been shown that many of these autoantibodies are directed against complexes that some proteins, such as glycoprotein I2 or prothrombin, form with phospholipids.
- Obstetric complications Obstetric complications are fundamentally: fetal death after the tenth week of pregnancy, the birth of premature children, spontaneous abortions before the tenth week of pregnancy, intrauterine growth retardation, eclampsia and pre-eclampsia.
- PCA EPCR Activated protein C
- S protein (its non-enzymatic cofactor)
- EPCR Endothelial receptor of activated PC / PC
- EPCR is a glycoprotein that is expressed in the membrane of endothelial cells and that specifically binds PC and PCA with high affinity.
- EPCR For EPCR to be functional, it must be attached to a phospholipid molecule that stabilizes its three-dimensional structure. The binding of the PC to the EPCR significantly increases its activation by the thrombin-thrombomodulin complex on the endothelial cell surface. EPCR's mission is to concentrate the PC on the endothelial surface and present it to the thrombin-thrombomodulin complex thus favoring efficient PC activation. The EPCR increases (approximately nine times) the activation rate of PC on the surface of endothelial cells in vivo and is therefore responsible for 90% of circulating PCA levels.
- the PCA activates the active protease-activated receptor-1 that generates a "cytoprotective" cellular signal and blocks apoptosis.
- the EPCR is expressed mainly in the endothelium of the veins and arteries, especially in those of large and medium caliber, and, in addition, it is expressed very intensely in the syncytiotrophoblast. In these places the EPCR prevents thrombosis and favors the good cellular functioning both of the endothelium as of the syncytiotrophoblast. There is growing evidence to support EPCR's role in maintaining pregnancy since deletion of the EPCR gene in "knock out" mice causes placental thrombosis and early embryonic death in these mice.
- the present invention relates to a method for the determination of anti-EPCR autoantibodies (IgG, IgA and IgM) in a sample from a subject.
- IgG, IgA and IgM anti-EPCR autoantibodies
- vascular diseases such as arterial thrombosis, for example, myocardial infarction (determined in both patients with SAF and in patients without SAF), or cerebral ischemic stroke (determined in patients with SAF), or venous thrombosis (determined in patients with SAF), as well as in patients with obstetric complications, such as with fetal death (determined in both women with SAF and in women without SAF) or repeat abortions (determined in patients with FAS).
- the authors of the present invention have discovered that the presence of anti-EPCR autoantibodies in serum or plasma of patients with autoimmune diseases, and / or in patients with vascular diseases and / or in patients with obstetric complications, is increased compared to samples from of healthy, unaffected subjects of such pathologies. These evidences make said anti-EPCR autoantibodies a useful marker to assess in vitro the risk and predisposition of a subject to develop a pathology related to the presence of high levels of autoantibodies against EPCR, such as an autoimmune disease, a disease vascular or obstetric complications.
- the presence of anti-EPCR autoantibodies in patients with FAS and their relationship with fetal death has been investigated.
- FIGURES Figure 1 illustrates the expression of rshEPCR in Pichia pastoris.
- the rshEPCR was purified from the supernatant of stably transformed P. pastoris cells, as described in the section on Materials and Methods (see Example). 10 ⁇ l of each of three fractions containing rhsEPCR were separated by SDS-PAGE and the proteins were detected using GELCODE Blue (A) or by Western blotting with the anti-myc monoclonal antibody (Invitrogen) (B).
- Figure 2 shows the comparison of the level of anti-EPCR autoantibodies in patients diagnosed with FAS and in controls. The levels of anti-EPCR autoantibodies are shown.
- Figure 3 shows the effect of anti-EPCR autoantibodies on the generation of PCA by endothelial cells, where the generation of PCA can be observed in the presence of anti-EPCR autoantibody of patient M isotype C compared to the generation of PCA in the absence of PCA antibody and in the presence of non-inhibitory antibody. 2-4 independent experiments were performed for each condition.
- the term "subject” refers to a member of a species of a mammalian animal, and includes, but is not limited to, domestic animals, primates and humans; The subject is preferably a human being, male or female, of any age or race.
- autoimmune diseases refers to those disorders in which an individual's immune system reacts against their own tissues, determining a wide variety of diseases; By way of illustration, said autoimmune diseases include, among others, SAF, systemic lupus erythematosus, rheumatoid arthritis, autoimmune vasculitis, etc.
- vascular diseases refers to those diseases that affect the blood vessels.
- vascular diseases When it affects an arterial vessel they are characterized by the lack of blood supply to a territory determined of the organism and is usually secondary to the occlusion of some artery, caused by an atherosclerotic lesion of the wall or by a thrombosis, or both at the same time.
- a venous vessel When it affects a venous vessel, it is characterized by difficulty in the return of blood to the heart from the territory of the affected organism and is usually secondary to occlusion of the venous vessel by a thrombus.
- microcirculation When it affects microcirculation it is characterized by the difficulty of the organ whose microcirculation is affected to perform its function.
- said vascular diseases include, among others, arterial vascular diseases, such as myocardial infarction, stroke, transient cerebral accident, limb ischemia, atherosclerosis, aneurysm, etc., as well as venous vascular diseases, such as venous thrombosis. superficial and deep, pulmonary embolism, etc., and vascular diseases (thrombosis) of the microcirculation as the organic failure that occurs during infections or autoimmune diseases.
- arterial vascular diseases such as myocardial infarction, stroke, transient cerebral accident, limb ischemia, atherosclerosis, aneurysm, etc.
- venous vascular diseases such as venous thrombosis. superficial and deep, pulmonary embolism, etc.
- vascular diseases thrombosis of the microcirculation as the organic failure that occurs during infections or autoimmune diseases.
- obstetric complications refers to those disorders that affect the development of pregnancy, both those that affect the mother and those that affect the embryo or the fetus, such as, among others, abortion, fetal death, birth premature, intrauterine growth retardation, eclampsia and pre-eclampsia.
- autoantibody refers to antibodies produced by a subject and directed or specific against structures and tissues of the body itself that produces them, such as, for example, antiplatelet autoantibodies, antithyroid autoantibodies, red blood cell autoantibodies, etc.
- anti-EPCR autoantibody refers to immunoglobulins or antibodies produced by the subject himself and specifically directed against the EPCR of his own tissues.
- epitopope refers to an antigenic determinant of a protein such as the amino acid sequence of the protein that a specific antibody recognizes.
- peptide and “polypeptide” refer to molecular chains of amino acids that represent a protein fragment.
- protein and “peptide” are used interchangeably.
- the present invention is based on the discovery that the production of anti-EPCR autoantibodies in patients with autoimmune diseases, and / or in patients with vascular diseases and / or in patients with obstetric complications, is increased compared to samples from healthy subjects.
- anti-EPCR autoantibodies a useful marker to assess in vitro the risk and predisposition of a subject to develop a pathology related to the presence of elevated levels of anti-EPCR autoantibodies.
- high levels of anti-EPCR autoantibodies refers to UA levels (arbitrary units) equal to or greater than the 50th percentile of the population normal, including, for example, UA levels equal to or greater than the 60th percentile of the normal population, equal to or greater than the 70th percentile of the normal population, equal to or greater than the 80th percentile of the normal population, equal to or greater than the 90th percentile of the normal population, and equal to or greater than the 95th percentile of the normal population.
- each subject will have a determined UA value of anti-EPCR autoantibodies and there will be a UA value of anti-EPCR autoantibodies in which above that value are 50% of the analyzed population, said value being the 50th percentile ; Obviously, there will also be a value above which 40% of the normal subjects tested are present and that value constitutes the 60th percentile. also other values above which will be 30%, 20%, 10% and 5% of the normal subjects tested, said values being the 70, 80, 90 and 95 percentiles, respectively.
- the present invention relates to a method for detecting the presence of high levels of autoantibodies against the endothelial receptor of activated PC / PC (EPCR) in a sample, characterized in that it comprises the in-quantification of autoantibodies against EPCR in said sample. coming from a subject.
- EPCR activated PC / PC
- autoimmune disease for example, SAF, systemic lupus erythematosus, rheumatoid arthritis, autoimmune vasculitis, etc.
- a vascular disease for example, an arterial vascular disease, such as infarction myocardium, stroke, transient stroke, limb ischemia, atherosclerosis, aneurysm, thrombosis, etc., or a venous vascular disease, such as superficial or deep venous thrombosis, pulmonary embolism, etc., or a microcirculation vascular disease
- obstetric complications for example, abortion, fetal death, premature birth, intrauterine growth retardation, eclampsia, pre-eclampsia, etc.
- the method object of the present invention is applied to the determination of the variation of the levels of anti-EPCR autoantibodies over time. Said determinations object of the present invention will be
- Said method comprises a step of obtaining the individual's sample, such as a serum or plasma sample, which can be obtained by any conventional method, for example, by a blood collection.
- Samples may be obtained from previously diagnosed, or undiagnosed, subjects of said autoimmune or vascular diseases, or with obstetric complications; or also of a subject under treatment, or who has been previously treated against such diseases or complications.
- the detection and quantification of said anti-EPCR autoantibodies is carried out by means of an immunological test coupled to a marker that allows to detect and quantify the formation of specific antigen-antibody complexes, for example, an immunochromatographic test.
- an immunological assay in which the marker is a fluorescent marker, an isotope, a heavy metal, an enzyme, a luminescent marker, a chemiluminescent marker, a chromogen, etc.
- assays which can be used in the present invention, which use unlabeled antibodies (primary antibody) and labeled antibodies (secondary antibody); These techniques include Western blotting or Western blotting, ELISA (Enzyme-Linked immunosorbent assay or enzyme linked immunosorbent assay), RIA (Radioimmunoassay or Radioimmunoassay), etc.
- the preferred immunoassay in the method of the invention that allows the detection and / or quantification of said anti-EPCR autoantibodies is an ELISA, comprising: a) immobilizing on a solid support a polypeptide comprising the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody; b) incubating said immobilized polypeptide with a sample suspected of containing anti-EPCR autoantibodies from said subject, for a period of time sufficient to allow the binding of said antibodies to the immobilized polypeptide and the formation of anti-EPCR polypeptide-autoantibody complexes; c) withdrawing the sample not bound to said immobilized polypeptide; d) incubating said anti-EPCR autoantibody complexes with a second antibody conjugated to an enzyme, wherein said second antibody is an antibody capable of binding to said anti-EPCR autoantibodies.
- Said polypeptide comprising the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody may well be a polypeptide comprising the amino acid sequence of the full length EPCR , or a polypeptide comprising the amino acid sequence of an EPCR fragment that contains at least one epitope capable of being recognized by an anti-EPCR antibody.
- said polypeptide is a fusion protein comprising: (i) a region A consisting of a polypeptide containing the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR antibody, and (ii) a region B consisting of a polypeptide comprising an amino acid sequence useful for the isolation or purification of said fusion protein and / or an amino acid sequence useful for anchoring said protein melting to a solid support. Said region B may be attached to the amino terminal end of said region A or to the carboxyl terminal end of said region A.
- said region A comprises the amino acid sequence of the soluble part of human EPCR.
- Region B comprises an amino acid sequence useful for the isolation or purification of the previously defined fusion protein and / or a sequence of amino acids useful for anchoring said fusion protein to a solid support.
- the amino acid sequence useful for the isolation or purification of said fusion protein may also act as an amino acid sequence useful for anchoring said fusion protein to a solid support and vice versa.
- region B comprises an amino acid sequence useful for the isolation or purification of a fusion protein and an amino acid sequence useful for anchoring a fusion protein to a solid support.
- said amino acid sequence useful for isolating or purifying a fusion protein and / or said amino acid sequence useful for anchoring a fusion protein to a solid support can be, for example, Arg-tag, His-tag , FLAG-tag, Strep-tag, an epitope capable of being recognized by an antibody, such as c-myc-tag, SBP-tag, S-tag, calmodulin binding peptide, cellulose binding domain, binding domain to chitin, glutathione S-transferase-tag, maltose binding protein, NusA, TrxA, DsbA, Avi-tag, etc.
- said region B is constituted by a polypeptide comprising an epitope capable of being recognized by an antibody (such as the c-myc epitope, recognized by an anti-c-myc antibody) and a histidine tail (His -tag).
- an antibody such as the c-myc epitope, recognized by an anti-c-myc antibody
- His -tag histidine tail
- the Example that accompanies this description describes the obtaining of a polypeptide, called rhsEPCR, consisting of a fusion protein comprising the amino acid sequence of the soluble part of human EPCR (hsEPCR), the amino acid sequence corresponding to the epitope c -myc and a histidine tail and whose amino acid sequence is shown in SEQ ID NO: 3.
- the polypeptide to be used in the method of the invention can be obtained by conventional methods, for example, by expression in a suitable expression system .
- the second antibody to be used in the aforementioned ELISA is an immunoglobulin isotype specific antibody and is derived from a different species from the sample tested, which allows the isotype of the anti-EPCR autoantibodies to be characterized.
- said second immunoglobulin isotype specific antibody is selected from an anti-human IgG antibody, an anti-human IgM antibody, an anti-human IgA antibody, and mixtures thereof.
- said second antibody is conjugated to a label that allows the detection of complex, such as an enzyme, for example, peroxidase, alkaline phosphatase, etc.
- the invention provides a method for assessing the risk and predisposition of a subject to develop a pathology related to the presence of elevated levels of autoantibodies against the endothelial receptor of activated PC / PC (EPCR) in said subject, which it comprises the in vitro quantification of autoantibodies against EPCR in a sample of said subject.
- EPCR activated PC / PC
- the pathology related to the presence of elevated levels of autoantibodies against EPCR in a subject is selected from an autoimmune disease, for example, SAF, systemic lupus erythematosus, rheumatoid arthritis, autoimmune vasculitis, etc .; a vascular disease, for example, an arterial vascular disease, such as myocardial infarction, stroke, transient cerebral accident, limb ischemia, atherosclerosis, aneurysm, thrombosis, etc., or a venous vascular disease, such as superficial venous thrombosis, deep vein thrombosis, pulmonary embolism, etc., or a microcirculation vascular disease such as a microcirculation thrombosis, organic failure that occurs during infections or autoimmune diseases, etc., and obstetric complications, for example, abortion, fetal death , premature birth, intrauterine growth retardation, eclampsia, pre-eclampsia,
- the method provided by the present invention is based on the subjects diagnosed with a disease Autoimmune, vascular or obstetric complications have high levels of anti-EPCR autoantibodies, compared to the corresponding levels in samples from subjects without a clinical history of such diseases or obstetric complications.
- the method for assessing the risk and predisposition of a subject to develop a pathology related to the presence of high levels of anti-EPCR autoantibodies provided by this invention is completed by comparing the levels of autoantibodies determined in the sample of the subject in question with the normal levels, normal levels being understood as those of a given population of normal subjects as indicated above when defining the expression "elevated levels”. Said method is based on immunological assays previously described in this section.
- the invention in another aspect, relates to a method for initorizing in vitro the effect of the therapy administered to a subject presenting a pathology related to the presence of high levels of anti-EPCR autoantibodies in said subject, which comprises the quantification in vi tro of said anti-EPCR autoantibodies in a sample of said subject.
- the method is carried out as previously mentioned, although, in this case, the samples come from subjects previously diagnosed with an autoimmune or vascular disease, or who have suffered some obstetric complication, undergoing therapeutic treatment, and can analyze The effect of therapy, that is, its effectiveness and effectiveness, applied to the subject under treatment in order to, for example, maintain the therapy or modify it.
- the invention relates to the use of anti-EPCR autoantibodies in a method for assessing the presence of high levels of autoantibodies against EPCR in a sample from said subject.
- said presence of high levels of anti-EPCR autoantibodies is related to a pathology selected from an autoimmune disease, a vascular disease and obstetric complications.
- An increased level of anti-EPCR autoantibodies is associated with an increased risk or predisposition to develop a pathology related to the presence of elevated levels of anti-EPCR autoantibodies in a subject, such as an autoimmune disease, a vascular disease and / or obstetric complications. .
- the invention relates to the use of a polypeptide comprising the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody, in a method to evaluate the presence of autoantibodies against the EPCR endothelial receptor in a sample.
- Said method comprises the detection and / or quantification in vitro of anti-EPCR autoantibodies in said sample.
- said pathology related to the presence of high levels of anti-EPCR autoantibodies is selected from an autoimmune disease, a vascular disease and obstetric complications.
- said polypeptide comprising the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody is a polypeptide as previously defined when describing the ELISA to detect and / or quantify anti-EPCR autoantibodies.
- said polypeptide is called rhsEPCR (Example), consisting of a fusion protein comprising the amino acid sequence of the soluble part of human EPCR (hsEPCR), the amino acid sequence corresponding to the c-myc epitope and a histidine tail, and whose amino acid sequence is shown in SEQ ID NO: 3.
- the invention in another aspect, relates to a kit for evaluating in vitro the presence of high levels of anti-EPCR autoantibodies, comprising a polypeptide that It comprises, in turn, the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody.
- said polypeptide comprising the amino acid sequence of the EPCR or a fragment thereof containing at least one epitope capable of being recognized by an anti-EPCR autoantibody is a polypeptide as previously defined when describing the ELISA to detect and / or quantify anti-EPCR autoantibodies.
- said polypeptide is called rhsEPCR (Example), consisting of a fusion protein comprising the amino acid sequence of the soluble part of human EPCR (hsEPCR), the amino acid sequence corresponding to the c-myc epitope and a histidine tail and whose amino acid sequence is shown in SEQ ID NO: 3.
- said kit is used to assess the risk and predisposition of an individual in vitro. to develop a pathology associated with the presence of elevated levels of anti-EPCR autoantibodies, selected from an autoimmune disease, a vascular disease and obstetric complications.
- EXAMPLE 1 Use of anti-EPCR autoantibodies as markers for the risk and predisposition of a subject to the development of pathologies related to the presence of high levels of said autoantibodies
- the study was approved by the ethics committees of the inventors' institution and informed consent was obtained from all patients.
- the inclusion of patients and controls, informed consent and blood sample collection took place at least 6 months (6-12 months) after fetal death. Blood samples were collected, processed and stored at -80 ° C, according to the conventional procedures The collection procedures were identical in all cases and controls.
- hsEPCR soluble human EPCR
- sequence of soluble human EPCR (hsEPCR) has been amplified, which comprises the extracellular domain without its signal peptide or the transmembrane and intracellular domains ( residues 1-139, numbering corresponding to the mature form of the protein after signal peptide processing) by polymerase chain reaction (PCR) with the initiators SEQ ID NO: 1 and SEQ ID NO: 2, which added a Clal and other Notl restriction site at the 5 'and 3' ends respectively, using cDNA of endothelial cells as template.
- PCR polymerase chain reaction
- SEQ ID NO: 3 shows the sequence of the rhsEPCR obtained, deduced from the DNA sequence, which comprises the residues added by the cloning technique employed, the residues of the extracellular region of the human rhsEPCR, the c-myc epitope, and the tail of 6 histidines.
- yeast pastoris colonies transformed with the vector containing the rhsEPCR coding sequence which in turn contains the zeocin resistance gene were grown in 4 ml of BMY medium [1% of (w / v) yeast extract, 2% (w / v) peptone, 100 mM potassium phosphate (pH 6.0), 1, 34% (w / v) of yeast nitrogen source with ammonium sulfate, 4x10-5% (w / v) of biotin] supplemented with 1% (v / v) glycerol (BMGY) and incubated at 28-30 ° C for about 18 hours with stirring.
- BMY medium 1% of (w / v) yeast extract, 2% (w / v) peptone, 100 mM potassium phosphate (pH 6.0), 1, 34% (w / v) of yeast nitrogen source with ammonium sulfate, 4x10-5% (w / v) of biotin
- the cells were collected by centrifugation at 2,000 g for 5 minutes at room temperature. The supernatant was discarded and the induction was induced. expression of rhsEPCR with 1% methanol for 18 hours. For this, the cells were resuspended in 3 ml of BMY supplemented with 0.5% (w / v) methanol and incubated for 18 hours at approximately 28-30 ° C with vigorous agitation. After induction, samples from the conditioned medium were loaded into 12% NuPAGE Bis-Tris gels (Invitrogen, Carlsbad, CA) and rhsEPCR was detected by Western Blot using the anti-myc monoclonal antibody (Invitrogen).
- the colony that secreted the highest concentration of rhsEPCR was selected.
- the metabolism of methanol (fast or slow metabolizer) of the colonies was studied, which allowed establishing the optimal expression conditions for the most appropriate colony.
- rhsEPCR was purified from the supernatants of yeast cultures by a 3-step purification process comprising metal affinity chromatography, anion exchange and gel filtration chromatography. For this, the culture supernatant was concentrated and dialyzed against sodium phosphate 100 mM, 10 M NaCl, pH 7.6, and then subjected to metal affinity chromatography on a 5 ml Hitrap column (Amersham Biosciences, Little Chalfont, United Kingdom) loaded with copper.
- the fraction that bound to the column was eluted with a buffer containing ethylenediaminetetraacetic acid (EDTA) and dialyzed against 20 mM Tris-HCl (pH 7.6) without NaCl, and then subjected to a chromatography of anion exchange in a Resource Q column (Amersham Biosciences) and elution with a 0.0-300 mM NaCl gradient in a volume equivalent to that of 20 columns.
- the eluted fractions containing the rhsEPCR were pooled and concentrated by centrifugal ultrafiltration and then applied to a Superdex 75-HR10 / 30 column (Amersham Biosciences) to effect gel filtration.
- the purified protein concentration was determined using the BCA total protein assay (Pierre, Rockford, IL) and bovine serum albumin (BSA) standards.
- BCA bovine serum albumin
- To detect the purified rhsEPCR the samples were loaded into 12% gels of NuPAGE Bis-Tris (Invitrogen, Carlsbad, CA) and electrophoresis was performed under reducing conditions followed by Coomassie blue staining. An electrophoresis gel was subjected to electro lottingr and rhsEPCR was detected with the anti-myc monoclonal antibody (Invitrogen). To estimate the molecular weight of the rhsEPCR, a molecular weight standard included in each electrophoresis gel was used.
- ELISA for the determination of anti-EPCR autoantibodies in serum or plasma
- the levels of anti-EPCR autoantibodies of the IgG, IgA or IgM isotype were determined separately, since these are the most frequently found in patients with autoimmune disorders in which detect antibodies directed against any of their own structures (autoantibodies).
- 96-well microplates (Costar, Acton, MA, USA) were upholstered with 100 ⁇ l / well of an anti-c-myc monoclonal antibody (Invitrogen, USA) at 1.5 ⁇ g / ml in a Na solution 2 C0 3 at 100 mmol / 1, pH 9.6, overnight at 4 ° C.
- This antibody is used as a capture antibody and is directed towards the added c-myc tag and present in the rhsEPCR. In this way, the rhsEPCR is anchored to the well while preserving its extracellular epitopes.
- TB 20 mM Tris, 150 mM NaCl, 0.05% T een-20, pH 7.4
- non-specific binding sites were blocked with 3% (w / v) BSA in TB at room temperature (RT) for 4.5 hours.
- 100 ⁇ l / well of a solution containing 3 ⁇ g / ml of rhsEPCR in TB supplemented with 1% BSA (TB1) was added and incubated for 2 hours at room temperature with gentle agitation.
- white wells were incubated with TB1 without rhsEPCR.
- 100 ⁇ l of a 1: 100 sample dilution was added to each well
- a sample was chosen to test on each plate (standard sample) which allowed to introduce a correction factor.
- the arbitrary units (AU) were defined as follows: for each patient sample (problem sample) the specific absorbance was calculated by subtracting the absorbance of the white wells and then multiplying by 1,000 and by a correction factor corresponding to the relationship between the specific absorbance of the standard sample tested on a given plate (reference plate) and on the plate where the test sample is tested.
- the coefficients of inter and intra-trial variation were evaluated with the use of five samples tested five times for the coefficient of inter-trial variation (less than 5%) and on three different occasions to calculate the coefficient of inter-trial variation (lower from 10%) .
- the cell line used was EA.h and 926, a transformed human endothelial cell line that has retained the ability to express thrombomodulin and EPCR (Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT
- the endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex Proc Nati Acad Sci US A. 1996; 93: 10212-6).
- 5xl0 4 cells per well of a 96-well plate were incubated with 0.02 U / ml thrombin (0.17 nM) (ERL, Swansea, United Kingdom) and increasing concentrations of PC (Baxter, Deerfield, IL, USA) oscillating between 50 and 1,000 nM in 20 mM Tris buffer, pH 7.4, supplemented with 150 mM NaCl, 5 mM CaCl 2 , 0.6 mM MgCl 2 , 1% BSA, 0.001% Tween-20 and 0.02% NaN 3 .
- Human IgM was eluted with 5 ml of 0.1 M glycine, pH 2.5 and collected in 100 ⁇ l of 1 M Tris, pH 9.0. The fraction containing human IgM was concentrated and dialyzed against TB supplemented with 5 mM CaCl 2 and 0.6 mM MgCl 2 , pH 7.4.
- rhsEPCR affinity column Preparation of a rhsEPCR affinity column
- the rhsEPCR (2 mg in 3 ml of 100 mM NaHC0 3 , pH 8.5) was attached to a HitTrap NHS-activated HP affinity column (Amersham Biosciences) following the manufacturer's instructions. After the reaction had been stopped with 0.1 M glycine, the rhsEPCR column was washed extensively with 2M NaCl. Thus, the rhsEPCR column was able to bind PC in TBS, pH 7.4, supplemented with 20 mM CaCl 2 and 0.6 mM MgCl 2 .
- the PC could be eluted from the column with TBS supplemented with ethylenediaminetetraacetic acid (EDTA) (data not shown). Since the column-linked rhsEPCR maintained its ability to bind to the PC, it should surely retain the native conformation and epitopes recognized by the autoantibodies. Therefore, the column thus prepared was suitable for removing anti-EPCR autoantibodies from a serum or plasma sample.
- EDTA ethylenediaminetetraacetic acid
- IgM, IgA and IgG was performed according to the chi- test square.
- the "odds ratio" (OR) Mart ⁇ nez-González MA, by Irala-Estevez J & Guillen Grima F, (1999), What is an odds ratio ?, Clinical Medicine, 112, 11: 416-422) and the interval 95% confidence were calculated as a measure of the association between SAF and anti-EPCR autoantibodies.
- OR Mart ⁇ nez-González MA, by Irala-Estevez J & Guillen Grima F, (1999), What is an odds ratio ?, Clinical Medicine, 112, 11: 416-422
- the interval 95% confidence were calculated as a measure of the association between SAF and anti-EPCR autoantibodies.
- the comparison between cases and controls for continuous variables and by categories was performed according to the t-test for paired samples and with the McNemar test, respectively.
- the association between the levels of anti-EPCR autoantibodies of IgG and IgM isotypes with ACL and with anti-cardiolipin antibodies of IgM isotype was evaluated with correlation coefficients for continuous variables and with the Mann-Whitney test for variables by categories.
- To assess the risk of fetal death associated with high levels of anti-EPCR autoantibodies of IgG and IgM isotypes a multiple regression analysis with pairs of cases and controls was used.
- the main independent variables were the levels of anti-EPCR autoantibodies of IgG and IgM isotypes by categories, according to the distribution of these immunoglobulins in the controls. Different cut-off points were used to determine the levels associated with a higher risk.
- rhsEPCR was first produced using the P. pastoris yeast expression system. Using the described protocol, more than 5 mg of rhsEPCR could be purified from a culture of P. pastoris. By polyacrylamide gel electrophoresis with sodium dodecyl sulfate (SDS-PAGE) and Western blot analysis with the anti-myc monoclonal antibody, the rhsEPCR appeared as a single and slightly heterogeneous band reflecting the different degrees of glycosylation, as previously described ( Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X,
- Biochemical characterization of anti-EPCR antibodies The anti-EPCR autoantibody fractions of IgM, IgA and IgG isotypes from patients with extremely high levels were purified from 1 ml of serum.
- Anti-EPCR autoantibodies in women with fetal death The frequencies of risk factors previously related to fetal death and anti-EPCR antibodies in the group of patients and controls studied are shown in Table 2.
- the 95th percentile of the IgG isotype anti-EPCR autoantibody levels in the control group was 94 AU. Of the 87 patients, 13 patients (15%) had values that exceeded that cut-off point compared to the 4 subjects in the control group.
- the OR not adjusted for fetal death in patients with anti-EPCR autoantibodies of IgG isotype greater than a 95% percentile was 4.3 (95% CI, 1.2 to 15.2). When the cut-off point was placed in the 90% percentile (88.4 AU), the OR was 2.3 (95% CI, 0.9 to 5.6). Additionally, a multivariate analysis was performed adjusting for potential confounding factors.
- Model (1) adjusted for antiphospholipid antibodies (i.e. ACL and anticardiolipin antibodies) and prothrombin G20210A and Model (2), in which the FVL but not the ACL was included.
- the OR associated with anti-EPCR autoantibodies of IgM isotype greater than the 95th percentile in Model (1) was 23.1 (95% CI, 2 to 266.3) and in Model (2) 31.0 (CI 95, 2 to 384.3).
- the OR associated with anti-EPCR autoantibodies of IgG isotype greater than the 95th percentile in Model (1) was 6.8 (95% CI, 1.2 to 38.4).
- DISCUSSION A method has been implemented, in particular, an ELISA, which allows the presence of autoantibodies against human EPCR to be detected.
- an ELISA which allows the presence of autoantibodies against human EPCR to be detected.
- a group of patients with FAS characterized by thrombosis and ACL have been studied and the presence of specific anti-EPCR autoantibodies, of IgM, IgG and IgA isotypes has been demonstrated for the first time in human pathology.
- the subgroup of patients with FAS with ACL has been studied because it has been related to an increased risk of thrombosis, and, therefore, it was thought that it would be a group with a high probability of presenting autoantibodies directly related to the clinical manifestation.
- EPCR is a molecule that is expressed in the endothelium of large blood vessels and in the trophoblast.
- the IgM and IgG immunoglobulins can fix and activate the complement, if these antibodies are directed against EPCR they could activate the complement in the endothelium and injure it by promoting thrombosis at that level.
- IgM isotype anti-EPCR autoantibodies defined as a value greater than the 95th percentile of the distribution of control subjects
- High levels of IgG isotype anti-EPCR autoantibodies were also a strong risk factor, but weaker than that of the IgM isotype, with a relative risk of 7 or 11 depending on the mathematical model used.
- the ACL and the IgM isotype anticardiolipin antibody were associated with an increased risk of fetal death but this association was attenuated in the multivariate model due, perhaps, because the information given by the classical antiphospholipid antibodies is due to Associated anti-EPCR autoantibodies, which could be an etiologic factor of fetal death rather than a mere risk marker.
- the presence of FVL and prothrombin G20210A was studied, which have recently been associated with an increased risk of late fetal death, with a higher risk in both the univariate and multivariate analysis associated with that polymorphism, but the risk was not statistically significant. probably due to the number of patients included in the study.
- this study shows, for the first time, the presence of anti-EPCR autoantibodies in patients with FAS and thrombosis.
- the presence of anti-EPCR autoantibodies of IgM and IgG isotypes increases the risk factor of the first episode of fetal death.
- These autoantibodies can themselves contribute to thrombosis and fetal death that occurs in the SAF and in the general population.
- EXAMPLE 2 Detection of anti-EPCR autoantibodies in women with myocardial infarction Study group: 142 women (age, 39 + 5 years, mean ⁇ standard deviation) with myocardial infarction and 142 healthy women (age, 39 + 5 years) matched by age and geographical origin. The classic risk factors of myocardial infarction (hypertension, hypercholesterolemia, diabetes, smoking and oral contraceptive consumption) were studied. The anti-EPCR IgG, IgM and IgA autoantibodies were determined in plasma samples following the ELISA assay protocol described in the "Materials and Methods" section (Example 1).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002555783A CA2555783A1 (en) | 2004-02-06 | 2005-02-03 | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies |
MXPA06008799A MXPA06008799A (es) | 2004-02-06 | 2005-02-03 | Metodo para evaluar el riesgo y la predisposicion desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr. |
AU2005210776A AU2005210776A1 (en) | 2004-02-06 | 2005-02-03 | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-EPCR autoantibodies |
JP2006551864A JP2007520713A (ja) | 2004-02-06 | 2005-02-03 | 抗epcr抗体の存在に関連する病状の進展の危険性および傾向の評価方法 |
AT05701698T ATE445163T1 (de) | 2004-02-06 | 2005-02-03 | Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln |
EP05701698A EP1722229B8 (en) | 2004-02-06 | 2005-02-03 | Method of assessing risk of and predisposition to the development of a pathology related to the presence of anti-epcr antibodies |
US10/588,740 US20070141625A1 (en) | 2005-02-03 | 2005-02-03 | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies |
DE602005017016T DE602005017016D1 (de) | 2004-02-06 | 2005-02-03 | Verfahren zur beurteilung der gefahr und veranlagung, eine mit dem vorliegen von anti-epcr-antikörpern verbundene symptomatik zu entwickeln |
BRPI0506635-2A BRPI0506635A (pt) | 2004-02-06 | 2005-02-03 | método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200400269A ES2239532B1 (es) | 2004-02-06 | 2004-02-06 | Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr. |
ESP200400269 | 2004-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005076000A1 true WO2005076000A1 (es) | 2005-08-18 |
WO2005076000A8 WO2005076000A8 (es) | 2005-10-27 |
Family
ID=34833893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2005/000046 WO2005076000A1 (es) | 2004-02-06 | 2005-02-03 | Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1722229B8 (es) |
JP (1) | JP2007520713A (es) |
CN (1) | CN1954216A (es) |
AT (1) | ATE445163T1 (es) |
AU (1) | AU2005210776A1 (es) |
BR (1) | BRPI0506635A (es) |
CA (1) | CA2555783A1 (es) |
DE (1) | DE602005017016D1 (es) |
ES (1) | ES2239532B1 (es) |
MX (1) | MXPA06008799A (es) |
RU (1) | RU2375716C2 (es) |
WO (1) | WO2005076000A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090286256A1 (en) * | 2008-05-19 | 2009-11-19 | Abbott Laboratories | Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides |
BRPI1013201A2 (pt) | 2009-05-05 | 2019-02-26 | Yeda res & development co ltd | meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo |
US20130035254A1 (en) * | 2010-02-12 | 2013-02-07 | Tel Hashomer Medical Research Infras | Diagnosis of systemic lupus erythematosus (sle) |
SG189391A1 (en) * | 2010-10-18 | 2013-05-31 | Nestec Sa | Methods for determining anti-drug antibody isotypes |
EA018848B1 (ru) * | 2010-10-20 | 2013-11-29 | Вадим Юльевич ШАНИН | Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции |
WO2012105838A1 (en) * | 2011-02-02 | 2012-08-09 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Anti-carbamylated protein antibodies and the risk for arthritis |
RU2586412C2 (ru) * | 2012-06-09 | 2016-06-10 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ оценки риска возникновения патологии беременности |
RU2517051C1 (ru) * | 2013-01-09 | 2014-05-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) | Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин |
CN104655860A (zh) * | 2013-11-21 | 2015-05-27 | 苏州中赢医疗科技有限公司 | 一种类风湿性关节炎的诊断标志 |
US10545144B2 (en) | 2013-12-31 | 2020-01-28 | Yeda Research And Development Co., Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
CN107533058A (zh) | 2015-03-01 | 2018-01-02 | 免疫阵列有限公司 | 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮 |
US20230043394A1 (en) * | 2019-12-30 | 2023-02-09 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0600088A1 (en) * | 1992-02-05 | 1994-06-08 | Yamasa Corporation | Solid-phase reagent and assay of antibody using the same |
US6037450A (en) * | 1997-06-27 | 2000-03-14 | Oklahoma Medical Research Foundation | Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor |
US6617145B2 (en) * | 1999-10-01 | 2003-09-09 | Amgen Inc | DNA molecules encoding fibrinolytically active polypeptide |
-
2004
- 2004-02-06 ES ES200400269A patent/ES2239532B1/es not_active Expired - Fee Related
-
2005
- 2005-02-03 JP JP2006551864A patent/JP2007520713A/ja not_active Withdrawn
- 2005-02-03 DE DE602005017016T patent/DE602005017016D1/de not_active Expired - Fee Related
- 2005-02-03 CA CA002555783A patent/CA2555783A1/en not_active Abandoned
- 2005-02-03 AT AT05701698T patent/ATE445163T1/de not_active IP Right Cessation
- 2005-02-03 RU RU2006132064/15A patent/RU2375716C2/ru active
- 2005-02-03 MX MXPA06008799A patent/MXPA06008799A/es unknown
- 2005-02-03 AU AU2005210776A patent/AU2005210776A1/en not_active Abandoned
- 2005-02-03 WO PCT/ES2005/000046 patent/WO2005076000A1/es active Application Filing
- 2005-02-03 CN CNA2005800068535A patent/CN1954216A/zh active Pending
- 2005-02-03 BR BRPI0506635-2A patent/BRPI0506635A/pt not_active IP Right Cessation
- 2005-02-03 EP EP05701698A patent/EP1722229B8/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0600088A1 (en) * | 1992-02-05 | 1994-06-08 | Yamasa Corporation | Solid-phase reagent and assay of antibody using the same |
US6037450A (en) * | 1997-06-27 | 2000-03-14 | Oklahoma Medical Research Foundation | Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor |
US6617145B2 (en) * | 1999-10-01 | 2003-09-09 | Amgen Inc | DNA molecules encoding fibrinolytically active polypeptide |
Non-Patent Citations (2)
Title |
---|
GU J.M. ET AL: "Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality.", THE JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 277, no. 45, November 2002 (2002-11-01), pages 43335 - 43343, XP008042848 * |
OOSTING J.D. ET AL: "Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.", BLOOD., vol. 81, no. 10, May 1993 (1993-05-01), pages 2618 - 2625, XP008070727 * |
Also Published As
Publication number | Publication date |
---|---|
JP2007520713A (ja) | 2007-07-26 |
EP1722229B8 (en) | 2009-11-25 |
BRPI0506635A (pt) | 2007-05-08 |
RU2006132064A (ru) | 2008-03-20 |
DE602005017016D1 (de) | 2009-11-19 |
MXPA06008799A (es) | 2007-04-17 |
CA2555783A1 (en) | 2005-08-18 |
RU2375716C2 (ru) | 2009-12-10 |
ES2239532A1 (es) | 2005-09-16 |
WO2005076000A8 (es) | 2005-10-27 |
EP1722229A1 (en) | 2006-11-15 |
AU2005210776A1 (en) | 2005-08-18 |
ES2239532B1 (es) | 2006-11-01 |
ATE445163T1 (de) | 2009-10-15 |
EP1722229B1 (en) | 2009-10-07 |
CN1954216A (zh) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005076000A1 (es) | Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr | |
US20070141625A1 (en) | Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies | |
ES2720594T3 (es) | Anticuerpos anti-fXI y métodos de uso | |
ES2674570T3 (es) | MCAM como un biomarcador para la homeostasis de líquidos | |
JP5604111B2 (ja) | 子癇前症の診断及び治療 | |
ES2406266T3 (es) | Antígeno CD14 soluble novedoso | |
JP2013078319A (ja) | フォンビルブランド因子特異的切断酵素を主成分とする診断薬および医薬品 | |
ES2841739T3 (es) | Método para la determinación selectiva del factor de crecimiento placental 2 | |
ES2948446T3 (es) | Adrenomedulina para la valoración de la congestión en un sujeto con insuficiencia cardiaca aguda | |
KR101670103B1 (ko) | 폰빌레브란트 인자의 adamts13-매개 생체내 절단을 측정하는 방법 및 그의 사용 | |
Sarig | ADAMTS-13 in the diagnosis and management of thrombotic microangiopathies | |
ES2387880T3 (es) | Procedimiento de detección de trombosis mediante la medición de la proteasa de escisión del factor de von Willebrand | |
KR20140030188A (ko) | Igfbp 단편을 이용한 심혈관 사건의 위험도 측정 방법 | |
Laffan et al. | 17 Investigation of a thrombotic tendency | |
Szpera-Gozdziewicz et al. | Relationship between the von willebrand factor plasma concentration and ultrasonographic doppler findings in pregnancies complicated by hypertensive disorders: A pilot study | |
JP6081714B2 (ja) | 高コレステロール血症と動脈硬化の検出方法 | |
EP3342861B1 (en) | Specifically purified anti-presepsin antibody | |
Zhang et al. | Complement component C4A and apolipoprotein AI in plasmas as biomarkers of the severe, early-onset preeclampsia | |
ES2529018T3 (es) | Métodos y uso para la evaluación de la gravedad de la enfermedad pulmonar obstructiva crónica (EPOC) | |
Yatsenko et al. | Polyclonal antibodies against human plasminogen: purification, characterization and application | |
JP6417118B2 (ja) | Pcsk9測定用標準物質 | |
Keeling | Fibrinolytic Abnormalities and Antiphospholipid Antibodies | |
Sato et al. | Anti-Factor XII Autoantibodies in Patients with Recurrent Pregnancy Loss Recognize the Second Epidermal Growth Factor–Like Domain | |
Boron et al. | TH Open | |
JP6338933B2 (ja) | Pcsk9関連薬剤のスクリーニング、又は、当該薬剤の投与効果の確認を行うためのpcsk9の測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (57) PUBLISHED ABSTRACT IN ENGHISH REPLACED BY CORRECT ABSTRACT |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/008799 Country of ref document: MX Ref document number: 2555783 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006551864 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005210776 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580006853.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005701698 Country of ref document: EP Ref document number: 2006132064 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005210776 Country of ref document: AU Date of ref document: 20050203 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007141625 Country of ref document: US Ref document number: 10588740 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005701698 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0506635 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10588740 Country of ref document: US |